GMP IPO Watch
Molbio Diagnostics IPO 2026: Public-Health Scale, Truenat Expansion, ₹939.7 Crore Issue and Day-2 Investment Analysis
Molbio Diagnostics IPO is open from August 10 to 12, 2026 at ₹768–₹807 per share. Explore ...
Read Article
M
Mainboard IPO
LISTED
BSE, NSE
MOLBIO
Molbio Diagnostics IPO
Molbio Diagnostics IPO details, live grey market premium (GMP), dates, price band, lot size, subscription & review.
Live GMP Today
₹120
+14.9%
Est. Listing: ₹927.00
Price Band
₹768 - ₹807
Per equity share
Lot Size
18 Shares
Min Invest: ₹14,526
Issue Size
₹939.7 Cr
Total Public Offering
Issue Dates
9 August 2026 – 11 August 2026
Bidding period
Subscription
70.26x
Total overall demand
Molbio Diagnostics IPO Details
Key facts at a glance| IPO Open Date | 9 August 2026 | IPO Close Date | 11 August 2026 |
|---|---|---|---|
| Basis of Allotment | 12 August 2026 | Listing Date | 16 August 2026 |
| Price Band | ₹768 - ₹807 per share | Face Value | ₹10 per share |
| Market Lot Size | 18 Shares | Min Investment (Retail) | ₹14,526 |
| Total Issue Size | ₹939.7 Cr | Issue Type | Book Built Issue IPO |
| Fresh Issue | — | Offer for Sale (OFS) | — |
| Listing At | BSE, NSE | Issue Category | Mainboard Issue |
| Registrar | TBA | ||
Molbio Diagnostics IPO Timetable (Tentative Dates)
| Event | Tentative Date | Status |
|---|---|---|
| IPO Open Date | 9 August 2026 | Confirmed |
| IPO Close Date | 11 August 2026 | Confirmed |
| Basis of Allotment | 12 August 2026 | Tentative |
| Initiation of Refunds | 14 August 2026 | Tentative |
| Credit of Shares to Demat | 14 August 2026 | Tentative |
| IPO Listing Date | 16 August 2026 | Tentative |
| Cut-off time for UPI Mandate Confirmation | 12 August 2026 (5:00 PM) | Deadline |
* Note: Timelines are tentative and subject to regulatory confirmation. UPI mandate approvals must be completed by 5:00 PM on the IPO closing day.
Molbio Diagnostics IPO Lot Size & Investment Details
Application limits for Retail and HNI investors| Application Category | Lots | Shares | Amount (at Cut-off) |
|---|---|---|---|
| Retail (Min) | 1 Lot | 18 Shares | ₹14,526 |
| Retail (Max) | 13 Lots | 234 Shares | ₹1,88,838 |
| S-HNI (Min) | 14 Lots | 252 Shares | ₹2,03,364 |
| S-HNI (Max) | 68 Lots | 1,224 Shares | ₹9,87,768 |
| B-HNI (Min) | 69 Lots | 1,242 Shares | ₹10,02,294 |
Molbio Diagnostics IPO Live GMP & Movement History
Daily unofficial grey market trends
Current Grey Market Premium
₹120 +14.9%
Estimated Listing Price
₹927.00
| Date | IPO GMP (₹) | Estimated Listing Price | Estimated Listing Gain (%) |
|---|---|---|---|
| 12 Aug 2026 | ₹138 | ₹945.00 | +17.10% |
| 10 Aug 2026 | ₹132 | ₹939.00 | +16.36% |
Disclaimer: Grey Market Premium (GMP) figures are purely unofficial and indicative rates traded in the unregulated grey market. GMP is highly volatile and does not guarantee the actual listing price. Always consult a SEBI registered investment advisor before bidding.
Molbio Diagnostics IPO Subscription Status
Demand breakdown by investor category
Retail
12.96x
QIB
186.39x
NII / HNI
49.80x
Total
70.26x
About Molbio Diagnostics
Molbio Diagnostics is a point-of-care diagnostics company that develops and manufactures healthcare technologies for diagnosing infectious and non-communicable diseases. The company’s core business revolves around its proprietary ‘Truenat’ platform, a portable, battery-operated polymerase chain reaction (PCR) system designed for use in resource-limited settings. This platform provides rapid and accurate test results within approximately one hour. The company’s primary source of revenue is the sale of its ‘Truenat’ devices and the recurring sale of compatible, disease-specific micro-PCR test kits. Molbio offers a wide range of tests for various infectious diseases, including tuberculosis, COVID-19, Hepatitis B and C, HIV, and HPV. Through its subsidiaries, the company also provides devices related to radiology and digital pathology.
Key Strengths
- Proprietary TruNAT platform enables rapid, point-of-care molecular diagnostics.
- Strong footprint in government and public health procurement programs.
- Wide disease coverage including TB, COVID-19, HIV, hepatitis and HPV.
- In-house R&D supported by integrated manufacturing capabilities.
- Global presence with products deployed across multiple countries.
Key Risks
- Heavy dependence on government and international aid agency funding.
- High revenue concentration from tuberculosis-related test kits.
- A limited number of large customers contribute a significant share of revenues.
- Regulatory delays may impact the commercialisation of new diagnostic tests.
- Demand fluctuations are linked to public health policies and funding cycles.
Molbio Diagnostics IPO Reservation & Share Quotas
The Molbio Diagnostics IPO follows the SEBI-prescribed reservation structure for a Book Built Issue. The public issue is allocated among Qualified Institutional Buyers (QIBs), Non-Institutional Investors (NIIs), Retail Individual Investors (RIIs), and Anchor Investors. The final allotment in each category will depend on investor participation and the basis of allotment finalized after the IPO closes.
The category-wise reservation details for the public issue are provided below.
| Investor Category | Shares Offered | Reservation (%) |
|---|---|---|
| Anchor Investor | – Shares | -% |
| Qualified Institutional Buyers (QIB) (Excluding Anchor) | – Shares | 50% |
| Non-Institutional Investors (NII) | – Shares | 15% |
| Retail Individual Investors (RII) | – Shares | 35% |
Note: The exact number of shares reserved for each investor category, including Anchor Investors, will be announced before the IPO opens for subscription. The final allocation will be completed in accordance with SEBI regulations and the approved issue structure.
Molbio Diagnostics IPO Anchor Investors
Molbio Diagnostics Limited has reserved a portion of its IPO for eligible Anchor Investors before the public issue opens for subscription. Anchor investors are Qualified Institutional Buyers (QIBs) who participate in the IPO one working day before the public issue, helping improve price discovery and strengthen market confidence in the offering.
The details below include the anchor bidding schedule, proposed allocation, issue size, and the applicable SEBI-prescribed lock-in periods. The final list of anchor investors and allocation details will be announced after the completion of the anchor placement process.
| Particular | Details |
|---|---|
| Anchor Bidding Date | August 7, 2026 |
| Anchor Investors List | To be announced |
| Shares Offered | [.] Shares |
| Anchor Issue Size | [.] Crores |
| Lock-in Period End Date (50% Shares – 30 Days) | 2026 |
| Lock-in Period End Date (Remaining 50% Shares – 90 Days) | 2026 |
Note: The final anchor investor list, number of shares allotted, anchor issue size, and exact lock-in period end dates will be updated after the completion of the anchor allocation process. The lock-in period for anchor investors will be applicable in accordance with SEBI regulations.
Molbio Diagnostics IPO Important Dates
| Particular | Dates |
|---|---|
| IPO Open Date | 10 Aug 2026 |
| IPO Close Date | 12 Aug 2026 |
| Basis of Allotment | 13 Aug 2026 |
| Refunds | - |
| Credit to Demat Account | - |
| IPO Listing Date | 17 Aug 2026 |
Note: The timeline for Molbio Diagnostics IPO is tentative and subject to change.
Molbio Diagnostics Promoters and Shareholding Pattern
The promoters of Molbio Diagnostics Limited have been instrumental in building the company's presence in the molecular diagnostics and medical technology sector. Following the IPO, the promoter group will continue to retain a significant ownership stake, while the public shareholding will increase through the fresh issue and Offer for Sale (OFS).
The table below presents the promoter and public shareholding pattern before and after the IPO based on the proposed issue structure.
Promoters of Molbio Diagnostics Limited
- Chandrasekhar Bhaskaran Nair
- Exxora Trading LLP
- Sangeetha Sriram
- Shiva Sriram
- Sowmya Sriram
- Sriram Natarajan
| Category | Pre IPO Shares | Pre IPO Holding | Post IPO Shares | Post IPO Holding |
|---|---|---|---|---|
| Promoter and Promoter Group | 52,597,450 | 46.65% | 4,34,31,450 | 37.69% |
| Others* | 60,162,300 | 53.35% | 7,18,08,546 | 62.31% |
| Total | 11,27,59,750 | 100% | 11,52,39,996 | 100% |
Note: The post-IPO shareholding pattern is based on the proposed issue structure and may change after the final allotment of shares. The promoter group will continue to hold a substantial stake in the company following its listing on the BSE and NSE.
Molbio Diagnostics Objects of the Issue & Utilisation of Proceeds
To Be Updated Soon
Molbio Diagnostics About the IPO
To be updated soon
Molbio Diagnostics Company Financial Report
To Be Updated Soon
Molbio Diagnostics Company Valuation & Key Performance Indicators
To Be Updated Soon
Molbio Diagnostics Peer Group Comparison
To Be Updated Soon
Molbio Diagnostics Lead Managers & Merchant Bankers
- Kotak Mahindra Capital Co. Ltd.
- IIFL Capital Services Ltd.
- Jefferies India Pvt. Ltd.
- Motilal Oswal Investment Advisors Ltd.
Molbio Diagnostics IPO FAQs
Molbio Diagnostics IPO opens for subscription on 9 August 2026 and closes on 11 August 2026.
The price band for Molbio Diagnostics IPO is set at ₹768.00 to ₹807.00 per share.
The minimum market lot size is 18 shares. A retail investor can apply for a minimum of 1 lot requiring an investment of 18 Shares (₹14,526).
The latest Grey Market Premium (GMP) for Molbio Diagnostics IPO is ₹120. GMP represents the unofficial premium at which shares trade prior to listing.
The basis of allotment for Molbio Diagnostics IPO is tentatively scheduled for 12 August 2026, and shares are expected to list on the stock exchanges on 16 August 2026.
The registrar details will be confirmed in the official prospectus.
Molbio Diagnostics IPO Analysis & Articles
